Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. | Johnson ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

Ocean Biomedical has signed a $32 million biobucks deal with a Polish biotech to secure the rights to a batch of preclinical ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching ...

The impact of positive data on TPM502 could extend beyond celiac disease. As Topas’ lead candidate, TPM502 is serving as a ...

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...

Forbion has unveiled its largest haul to date, as the European life-sciences-focused VC firm brings in over 2 billion euros ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

CMR Surgical obtained a de novo clearance from the FDA for its Versius surgical system, finally allowing its modular, ...